Delivery Order SPE2DB22D2108-SPE2DB25FU5MS
- Not listed
- The Defense Logistics Agency awarded a $10,308.12 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Eliquis 5 mg tablets (60-count packages). This is a firm fixed price, non-set-aside contract with a completion date of July 22, 2025, and performance location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a relatively small transaction within the company's extensive federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Eliquis 5 mg tablets (60-count packaging) valued at $3,484.49. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime vendor agreement running through December 2026. The delivery order carries an ultimate completion date of July...
- The Defense Logistics Agency awarded a $2,214.72 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Eliquis 5 mg tablets (60-count packages). This is a firm fixed-price contract with a completion date of August 14, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was competitively awarded with no set-aside designation. Performance will occur at...
- The Defense Logistics Agency awarded a $1,965.60 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Eliquis 2.5 mg tablets in quantities of 60 units. This non-competitive, firm fixed-price delivery order is set to be completed by August 11, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order issued under AmerisourceBergen's broader pharmaceutical supply agreements with the...
- The Defense Logistics Agency awarded a delivery order valued at $5,514.22 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count) on August 5, 2025, with completion scheduled for August 6, 2025. This competitive award, issued on a firm fixed-price basis with no set-aside designation, represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a $1,883.70 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Eliquis 2.5 mg tablets (60-count). This firm fixed-price contract is non-set-aside and scheduled for completion by July 24, 2025, with performance taking place at the contractor's headquarters in Conshohocken, Pennsylvania. The delivery order represents a single pharmaceutical procurement under AmerisourceBergen's existing contract vehicle with the agency. This award...
- The Defense Logistics Agency awarded a delivery order valued at $1,591.08 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packaging) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) valued at $3,271.68 with a firm fixed price structure and an ultimate completion date of August 12, 2025. This is a non-set-aside, competitively awarded delivery order executed under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), which is valued at $999.999 billion and...
- The Defense Logistics Agency awarded a delivery order valued at $1,965.60 to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count packages) on July 29, 2025, with completion targeted for July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical will be delivered to the Conshohocken, Pennsylvania location, which serves as AmerisourceBergen's corporate headquarters and primary distribution...
- The Defense Logistics Agency awarded a delivery order valued at $7,441.90 to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count units) under firm fixed pricing. The award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-competitive delivery against an existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery from its...
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5MSDelivery Order
The Defense Logistics Agency awarded a $1,965.60 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Eliquis 2.5 mg tablets (60 count). This firm fixed-price contract, with an ultimate completion date of August 19, 2025, represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The award was made without a set-aside designation through competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with place of performance at its corporate office location. This delivery order exemplifies AmerisourceBergen's role as a major pharmaceutical supplier within the federal healthcare system, particularly for military and veteran healthcare programs. The DLA Troop Support Medical contract vehicle enables the company to fulfill recurring pharmaceutical supply needs across multiple therapeutic domains on a global basis, supporting customers including the Defense Health Agency and U.S. Coast Guard. The Pharmaceutical Prime Vendor Global Program represents a strategic procurement approach designed to ensure reliable access to essential medications and medical supplies for the Department of Defense healthcare infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 8/18/25 |